EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MIF as an oncogenic driver of low‐heterogeneity melanomas

Thuy T Tran iD, Gabriela Athziri Sánchez-Zuno, Rajan P Kulkarni, Harriet M Kluger iD, Richard Bucala

Molecular Oncology · 2025

DOI: 10.1002/1878-0261.70031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2025. Verfasst von Thuy T Tran und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Carcinogenesis, Intramolecular Oxidoreductases, Macrophage Migration-Inhibitory Factors, Melanoma. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, CSRD VA, Kuni Foundation Discovery Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying targets involved in tumor evolution and immune escape is an active area of research in oncology. Macrophage migration inhibitory factor (MIF) is an upstream immunoregulatory cytokine that promotes transformed cell proliferation and survival, and generates a tumor‐permissive immune landscape of immunosuppressive myeloid and T cells. Shvefel and colleagues have identified a key role for MIF in tumor progression in melanoma clones with low tumor heterogeneity. These findings provide important insights into the potential therapeutic utility of MIF antagonists and support ongoing research to utilize MIF pathway inhibitors for improved therapeutic outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinogenesisIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMelanomaOncogenesAnimalsHumans

Stichwörter der Autor:innen

D‐dopachrome tautomeraseimmune resistancemacrophage migration inhibitory factormelanomatumor heterogeneitytumor‐associated macrophage

Substanzen

Intramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Section of Rheumatology, Allergy & Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Department of Dermatology, Oregon Health & Science University, Portland, OR, USA.

ORCID-Profile: Thuy T Tran, Harriet M Kluger

Förderung

  • NIDCR NIH HHS
  • CSRD VA
  • Kuni Foundation Discovery Grant
  • Karin Bain and John Kukral Foundation
  • National Institute of Health
  • NCI NIH HHS
  • U.S. Department of Veterans Affairs

Zitieren

APA

Tran, T. T., Sánchez-Zuno, G. A., Kulkarni, R. P., Kluger, H. M., & Bucala, R. (2025). MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology. https://doi.org/10.1002/1878-0261.70031

Vancouver

Tran TT, Sánchez-Zuno GA, Kulkarni RP, Kluger HM, Bucala R. MIF as an oncogenic driver of low‐heterogeneity melanomas. Molecular Oncology. 2025. doi:10.1002/1878-0261.70031

BibTeX
@article{Tran2025,
  author = {Tran, Thuy T and Sánchez-Zuno, Gabriela Athziri and Kulkarni, Rajan P and Kluger, Harriet M and Bucala, Richard},
  title = {MIF as an oncogenic driver of low‐heterogeneity melanomas},
  journal = {Molecular Oncology},
  year = {2025},
  doi = {10.1002/1878-0261.70031}
}
Kostenlos starten →